Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 93 от 240

Набира участници

Analysis of Influencing Factors of High-Order Aberrations of SMILE With Lenticule Retained

Small-incision Lenticule Extraction (SMILE) Surgery Corneal Higher-order Wavefront Aberrations Residual Lenticule

Analysis of Influencing Factors of High-Order Aberrations of SMILE with Lenticule Retained

Начало: 31.10.2024 Край: 31.10.2026 Възраст: 18–45 г.

China Second Affiliated Hospital of Nanchang University NCT06806085

Набира участници Фаза 2

Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity

Doxorubicin Induced Cardiomyopathy Breast Cancer

This is a randomized controlled clinical trial that aims to evaluate the safety and efficacy of Dapagliflozin as a cardioprotective in doxorubicin-induced cardiotoxicity in breast cancer patients.

Начало: 31.10.2024 Край: 01.10.2026 Възраст: 18–65 г.

Egypt Tanta University NCT06427226

Набира участници

Multicenter iTBS Neuromodulation for PTSD Treatment

Posttraumatic Stress Disorder

The proposed study aims to evaluate the efficacy of intermittent theta-burst transcranial magnetic stimulation (iTBS) targeting primary motor cortex (M1) as adjunct treatment for PTSD patients. The primary outcome measure includes changes in PTSD symptom severity, with secondary outcome measures focusing on negative moods improvements, quality of life and social/occupation functioning and functional connectivity of the brain.

Начало: 30.10.2024 Край: 01.06.2027 Възраст: 18–65 г.

China Second Affiliated Hospital, School of Medicine, Zhejian NCT06434766

Набира участници Фаза 3

MDMA-assisted Massed Prolonged Exposure for PTSD

Post-Traumatic Stress Disorder

The overall objective of this study is to pilot the VASDHS-adapted Emory MDMA-PE Protocol (aE-MDMA-PE) and assess the effect on clinician-rated PTSD symptoms in veterans who receive different doses of MDMA.

Начало: 25.10.2024 Край: 31.08.2027 Възраст: 18–64 г.

United States Healing Breakthrough NCT06117306

Набира участници

ATHNdataset Registry

Hemophilia Thrombosis Hemophilia A Hemophilia B +5

The Hemophilia Treatment Center (HTC) where you receive care is working with The American Thrombosis and Hemostasis Network (ATHN) to look at the quality of life of people with blood disorders and problems. Doctors, scientists, policymakers, and other health care providers need a large amount of information from a lot of people to answer scientific, public health, and policy questions about better ways to treat blood disorders. They will use the information from the ATHNdataset to answer these questions.

Начало: 25.10.2024 Край: 31.10.2055

United States American Thrombosis and Hemostasis Network NCT06820515

Набира участници Фаза 3

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Classic Follicular Lymphoma Follicular Lymphoma With Unusual Cytological Features

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.

Начало: 23.10.2024 Край: 31.03.2032 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT06337318

Набира участници

Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including Sickle Cell Disease Cystic Fibrosis Fragile X Syndrome +11

Cell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free DNA (cfDNA) in maternal plasma. Its presence in maternal plasma has allowed development of noninvasive prenatal diagnosis for single-gene disorders (SGD-NIPD). This can be performed from 9 weeks of amenorrhea and offers an early, safe and accurate definitive diagnosis without the miscarriage risk associated with invasive procedures. One of the major difficulties is distinguishing fetal genotype in the high background of maternal cfDNA, which leads to several technical and analytical challenges. Besides, unlike noninvasive prenatal testing for aneuploidy, NIPD for monogenic diseases represent a smaller market opportunity, and many cases must be provided on a bespoke, patient- or disease-specific basis. As a result, implementation of SGD-NIPD remained sparse, with most testing being delivered in a research setting. The present project aims to take advantage of the unique French collaborative network to make SGD-NIPD possible for theoretically any monogenic disorder and any family.

Начало: 23.10.2024 Край: 01.05.2027 Възраст: от 18 г.

France Assistance Publique - Hôpitaux de Paris NCT06147414

Набира участници

INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use

Systemic Lupus Erythematosus (SLE)

INTERSTELLAR study will generate critical prospective real-world evidence on the benefits of adding Anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients. The study will use clinical assessments that are relevant for SLE-treating physicians in routine clinical practice, as well as introduce a specific measure for skin manifestations to affirm the potency of anifrolumab in treating SLE-related skin manifestations. The study will use standardized objectives, inclusion/exclusion criteria and outcome measures across all countries participating in this study including GCC (Qatar, KSA), Mexico, CAMCAR (Costa Rica, Panama, Dominican Republic), Colombia, Argentina, Taiwan, and Egypt, and any other countries that may be included in the study, in order to facilitate a comparison and analysis across all countries included in this study.

Начало: 22.10.2024 Край: 30.04.2027 Възраст: от 18 г.

Kazakhstan AstraZeneca NCT06314282

Набира участници Фаза 3

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.

Начало: 21.10.2024 Край: 29.10.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +20 Pfizer NCT06551324

Набира участници Фаза 3

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Long COVID Sars-CoV-2 Infection Coronavirus Infections COVID-19

The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.

Начало: 21.10.2024 Край: 01.07.2027 Възраст: от 18 г.

United States Wes Ely NCT06631287

Набира участници

Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors

High-risk Neuroblastoma

The study participant is being asked to be in a research study called LEGACY, because you were treated for high-risk neuroblastoma (HR-NBL). Primary Objective To determine the feasibility of conducting comprehensive evaluations, leveraging the established SJLIFE (St. Jude Lifetime Cohort Study) study infrastructure, in survivors of HR-NBL (high-risk neuroblastoma) who are greater than 2 years from completion of contemporary therapy and were previously treated at SJCRH (St. Jude Children's Research Hospital). Exploratory Objectives * To describe the health outcomes of survivors of HR-NBL previously treated at SJCRH with contemporary era therapy who are greater than 2 years from completion of therapy. * To describe the relationship between patient outcomes and social determinants of health (SDOH) in survivors of HR-NBL previously treated at SJCRH with contemporary era therapy who are greater than 2 years from completion of therapy.

Начало: 21.10.2024 Край: 01.12.2028 Възраст: от 5 г.

United States St. Jude Children's Research Hospital NCT06480526

Набира участници Фаза 3

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Carcinoma, Non-Small-Cell Lung

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).

Начало: 21.10.2024 Край: 26.01.2038 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +28 Merck Sharp & Dohme LLC NCT06623422

Набира участници

NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Circulation Pilot

Preterm Patent Ductus Arteriosus Sepsis Asphyxia +3

Non-invasive tools for monitoring of course of disease are important and necessary in the treatment of pre-term/premature infants and sick neonates. For many years, the ultrasound group in Trondheim has been at the forefront in the development of new ultrasound technology for the diagnosis and monitoring of disease. Several methods previously developed in this research group are today widely used in hospitals around the world. In this project the investigators aim to test a new ultrasound technology that allows continuous monitoring of cerebral blood flow in sick neonates and pre-term children. This technology was CE-certified in October 2022, and in this project the investigators will test the CE-certified version with the newest available approved software.

Начало: 20.10.2024 Край: 31.12.2029 Възраст: до 12 г.

Norway St. Olavs Hospital NCT06646250

Набира участници Фаза 3

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)

The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV, respectively during the double-blinded treatment period (DBTP). At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first 52-week open-label treatment period (OLTP1). At the end of the first OLTP1, participants may begin a second 52-week OLTP2. After the OLTP2, the participants will enter a follow-up period (approximately 8 weeks) while off study drug. The participants will be in the study for up to 138 weeks. More information can be found here: https://clinicaltrials.argenx.com/advancenext

Начало: 18.10.2024 Край: 01.06.2028 Възраст: от 18 г.

Austria, Bulgaria, China +14 argenx NCT06544499

Набира участници Фаза 2

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

Diabetic Peripheral Neuropathic Pain

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)

Начало: 18.10.2024 Край: 30.05.2026 Възраст: 18–80 г.

Canada, France, Germany +3 Vertex Pharmaceuticals Incorporated NCT06619860

Набира участници Фаза 3

Nebulized Ketamine for the Treatment of Major Depressive Disorder

Severe Depression Moderate Depression Ketamine Midazolam +13

This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.

Начало: 16.10.2024 Край: 30.09.2027 Възраст: 18–88 г.

United States Theresa Jacob, PhD, MPH NCT06752759

Набира участници Фаза 2/3

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).

Начало: 16.10.2024 Край: 25.12.2026 Възраст: 12–17 г.

Italy, Poland, South Korea +2 UCB Biopharma SRL NCT06055959

Набира участници Фаза 1

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Pancreatic Ductal Adenocarcinoma Non-small Cell Lung Cancer HR+/HER2- Ductal and Lobular Breast Cancer Triple Negative Breast Cancer +1

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).

Начало: 15.10.2024 Край: 16.01.2031 Възраст: 18–100 г.

Belgium, Canada, France +7 Novartis Pharmaceuticals NCT06562192

Набира участници

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

Liver Neoplasms Primary Liver Cancer Secondary Liver Cancer Tumor Liver +1

The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristics may affect histotripsy success at 36 hours post-histotripsy procedure. Sub-studies to the BOOMBOX: Master Study will investigate specific populations and/or clinical questions with more stringent enrollment criteria, standardized testing criteria, and/or follow-up schedule. Any participant enrolled in the BOOMBOX: Master Study that also qualifies for a sub-study may enroll in the sub-study in parallel; sub-studies will be described in separate sub-study protocols. The BOOMBOX: Master Study will collect information about participants before, during, and after the histotripsy treatment procedure. All participants will be followed per standard clinical follow-up based on each site's clinical practice for up to 5 years after the initial histotripsy procedure or until completion of their follow-up in a sub-study, whichever is longer.

Начало: 14.10.2024 Край: 01.11.2031 Възраст: от 22 г.

United States HistoSonics, Inc. NCT06486454

Набира участници Фаза 2

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis Ulcerative Colitis Chronic

The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).

Начало: 10.10.2024 Край: 01.09.2028 Възраст: 18–75 г.

Argentina, Belgium, Canada +18 Eli Lilly and Company NCT06598943

1 … 91 92 93 94 95 … 240